GFM
TARS icon

GF Fund Management’s Tarsus Pharmaceuticals TARS Stock Holding History

GF Fund Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.9K Sell
904
-49
-5% -$3.13K ﹤0.01% 376
2026
Q1 		$66.9K Buy
953
+120
+14% +$8.38K ﹤0.01% 369
2025
Q4 		$68.2K Sell
833
-75
-8% -$5.6K ﹤0.01% 377
2025
Q3 		$54K Sell
908
-70
-7% -$3.45K ﹤0.01% 388
2025
Q2 		$39.6K Hold
978
– – ﹤0.01% 439
2025
Q1 		$50.2K Buy
978
+175
+22% +$8.65K ﹤0.01% 420
2024
Q4 		$44.5K Buy
+803
New +$36.5K ﹤0.01% 399

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GF Fund Management's TARS Position: Q2 2026 in Review

GF Fund Management reduced its Tarsus Pharmaceuticals (TARS) stake by 5.1% in Q2 2026, selling an estimated $3.13K and leaving 904 shares worth $56.9K. The position accounts for ﹤0.01% of the portfolio, ranked #376.

GF Fund Management first reported a position in TARS in Q4 2024 and has held it in 7 quarters since. The position peaked at $68.2K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • GF Fund Management held 904 shares of Tarsus Pharmaceuticals worth $56.9K as of Q2 2026.
  • GF Fund Management sold 49 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $3.13K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #376 holding.
  • GF Fund Management first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Tarsus Pharmaceuticals position peaked at $68.2K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.